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Abstract Pancreatic cancer (PC) mobilizes myeloid
cells from the bone marrow to the tumor where they
promote tumor growth and proliferation. Cancer stem
cells (CSCs) are a population of tumor cells that are
responsible for tumor initiation. Aldehyde dehydrogenase-1 activity in PC identifies CSCs, and its activity has been correlated with poor overall prognosis in
human PC. Myeloid cells have been shown to impact
tumor stemness, but the impact of immunosuppressive
tumor-infiltrating granulocytic and monocytic myeloidderived suppressor cells (Mo-MDSC) on ALDH1Bright
CSCs and epithelial to mesenchymal transition is not well
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understood. In this study, we demonstrate that Mo-MDSC
(CD11b+/Gr1+/Ly6G−/Ly6Chi) significantly increase the
frequency of ALDH1Bright CSCs in a mouse model of PC.
Additionally, there was significant upregulation of genes
associated with epithelial to mesenchymal transition. We
also found that human PC converts CD14+ peripheral
blood monocytes into Mo-MDSC (CD14+/HLA-DRlow/−)
in vitro, and this transformation is dependent on the activation of the STAT3 pathway. In turn, these Mo-MDSC
increase the frequency of ALDH1Bright CSCs and promote
mesenchymal features of tumor cells. Finally, blockade
of STAT3 activation reversed the increase in ALDH1Bright
CSCs. These data suggest that the PC tumor microenvironment transforms monocytes to Mo-MDSC by STAT3
activation, and these cells increase the frequency of ALDH1Bright CSCs. Therefore, targeting STAT3 activation may
be an effective therapeutic strategy in targeting CSCs in
PC.
Keywords Monocytic MDSC · Stem cell · Epithelial
to mesenchymal transition · Pancreatic cancer · STAT3
activity
Abbreviations
CCR2	Chemokine (C–C motif) receptor 2
CSC	Cancer stem cell
G-CSF	Granulocyte
colony-stimulating
factor
(CSF-3)
G-MDSC	Granulocytic myeloid-derived suppressor
cell
Mo-MDSC	Monocytic myeloid-derived suppressor cell
PC	Pancreatic cancer
STAT3	Signal transducer and activator of transcription 3
TAM	Tumor-associated macrophage
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Introduction
Pancreatic cancer (PC) is a highly aggressive malignancy
which is characterized by early metastasis and chemotherapeutic resistance [1]. PC has a uniquely dense stroma with
abundant leukocytes, which are predominantly myeloid
cells. These myeloid cells are heterogeneous; primarily
comprised of macrophages and monocytic and granulocytic myeloid-derived suppressor cells (Mo- and G-MDSC,
respectively) [2]. These cells are produced in the bone marrow, are actively recruited to the tumor microenvironment
by tumor-derived chemokines, and promote tumor growth
and spread through various mechanisms [3–5].
Their clinical importance is demonstrated by the finding
that in a number of cancer types including PC, increased
prevalence of myeloid cells in the tumor microenvironment is an independent prognostic factor for survival [6].
Tumor-associated myeloid cells have been shown to correlate with disease stage, resectability, and survival in PC [7,
8]. Typical of tumor-infiltrating myeloid cells is their ability to suppress antitumor immunity [9]. In addition, they
can also directly promote tumor cell proliferation, invasion
and thus facilitate metastasis, and therapeutic resistance
[7, 10].
Cancer stem cells (CSCs) are an important subpopulation of tumor cells which are capable of tumor initiation and are resistant to chemotherapy [11]. In PC, CSCs
were first identified as CD24+/CD44+/ESA+ cells [12].
Aldehyde dehydrogenase-1 (ALDH1) is a relatively new
marker which is an intracellular detoxifying enzyme originally identified as a phenotypic marker for hematopoietic
stem cells [13, 14]. We and others have previously demonstrated that ALDH1 is also an important marker of CSCs in
PC [15, 16]. In fact, patients having tumors with increased
ALDH1Bright CSCs have decreased progression free and
overall survival [16]. It is not entirely clear how levels of
ALDH1Bright CSCs are regulated, but there is mounting
evidence for a dynamic interplay between the stroma and
tumor cells which promotes epithelial to mesenchymal
transition (EMT) and tumor stemness [17, 18].
The role of mature tumor-associated macrophages
(TAMs) in promoting stemness in a murine model of
PC has been demonstrated by Mitchem et al. However,
the role of Mo-MDSC in PC is not well understood. In
this study, G-MDSC and Mo-MDSC from both mice
(G-MDSC: CD11b+/Gr1+/Ly6G+/Ly6Cmid, Mo-MDSC:
CD11b+/Gr1+/Ly6G−/Ly6Chi) and humans (G-MDSC:
Lin−/CD11b+/CD33+/CD15+, Mo-MDSC: Lin−/CD11b+/
CD33+/CD14+/HLA-DRlow/−) [19, 20] were assessed for
their impact on ALDH1Bright CSC in mouse and human
PC. We demonstrate that Mo-MDSC-infiltrating PC tumors
promote the ALDH1Bright CSC population by activation
of STAT3. We also show that cancer stem cell promoting
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activity can be blocked by inhibition of the STAT3 signaling pathway.

Materials and methods
Bone marrow samples from pancreatic cancer patients
and healthy controls and collection of PC tissue
from patients
Blood, bone marrow samples (N = 16), and tumor samples (N = 11) were collected from patients with resectable
PC at Barnes-Jewish Hospital (St. Louis, MO, USA). These
patients received no chemotherapy or radiation therapy prior
to surgery. Informed consent was obtained on all patients in
accordance with Institutional Review Board (IRB)-approved
protocol. Normal bone marrow was obtained from agematched healthy cancer free volunteers (N = 7). Bone marrow samples were collected in vacuum tubes containing lithium heparin (BD Vacutainer), and mononuclear cells were
isolated by Ficoll density centrifugation. Normal pancreas
tissue was collected from patients (N = 4) who were eligible for organ donation and had no malignant disease. Paraffin slides of normal human pancreas tissue (N = 5) were
obtained from Abcam, GeneTex, IHC world, and Imgenex.
Pancreatic cancer tissue microarray survival analysis
After obtaining IRB approval, tissue microarray (TMA)
studies were conducted on a cohort of 60 previously
untreated patients with pancreatic ductal adenocarcinoma
who underwent pancreaticoduodenectomy at Barnes-Jewish
Hospital. Patients did not receive neo-adjuvant therapy and
were typically treated with adjuvant chemotherapy. To construct the TMA, well-defined areas of tumor were demarcated and punched (1 mm diameter) from paraffin-embedded tumor blocks. An Aperio Scan-Scope XT Slide Scanner
(Aperio Technologies) system was used to acquire digital
images using a 20× objective. A tumor-specific nuclear
algorithm (IHC-MARK) developed in-house [15] was modified to quantify CD14, CD8, and ALDH1 expression.
STAT3 inhibitor
STATTIC (STAT3 inhibitor V) was obtained from
Calbiochem/EMD and used at doses less than the reported
IC50 (<20 µM) in vitro according to manufacturer instructions [21].
Cell lines
KCM and KCKO were a kind gift from Dr. Mukherjee
[22], Panc-1 and BxPC3 were purchased from ATCC, and
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Pan02 [23], from the Division of Cancer Treatment Tumor
Repository (NCI-Frederick Cancer Research and Development Center, Bethesda, MD).
Animal husbandry
GCSFR−/− mice were a kind gift from Daniel C. Link
(Internal Medicine/Division of Oncology). C57BL/6 and
NU/J mice were purchased from Jackson Laboratories.
Mice were maintained within the Washington University
Laboratory for Animal Care barrier facility and all studies
involving animals were approved by the Washington University School of Medicine Institutional Animal Studies
Committee.
Orthotopic model and preclinical animal cohorts
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For intracellular staining of cells, we used permeabilization buffer (eBioscience). We used CD45 (AF700; Biolegend, HI30), CD11b (AF488 and Pacific Blue; Biolegend, ICRF44), CD115 (PE; Biolegend, 9-4D21E4), CD14
(APC/Cy7; Biolegend, M5E2), CD15 (Pacific Blue; Biolegend, W6D3), CD68 (APC; Biolegend, CD68), HLA-DR
(PE/Cy7; BIolegend, L243), CD4 (PerCP/Cy5.5; eBioscience, RPA-T4), CD8 (Pacific Blue; Biolegend, SK1),
EpCAM (Pac Blue; Biolegend, 9C4), CD24(PE/Cy7; Biolegend, ML5), CD44 (APC/Cy7; Biolegend, IM7), and PPI
(Biolegend) for human tumors. For mice, we used CD45
(APC/Cy7; Biolegend, 30-F11), CD11b (APC; Biolegend, M1/70), Ly6C (PE/Cy7; Biolegend HK1.4), Ly6G
(Pacific Blue; Biolegend, 1A8), Gr-1 (AF700; Biolegend,
RB6-865), F4/80 (PerCpCy5.5; Biolegend, BM8), I-A/IE (AF488; Biolegend, M5/114.15.2), CD4 (AF700; Biolegend, GK1.5), CD8a (PE; Biolegend, 53-6.7), EpCAM
(PE/Cy7; Biolegend, G8.8), CD24 (PerCP/Cy5.5; Biolegend, M1/69), CD44 (APC/Cy7; Biolegend, IM7), and
PPI(Biolegend). Data acquisition and analysis were performed using an LSRII system (BD Biosciences), Aria II
High Speed Cell Sorter (BD Biosciences) for fluorescenceactivated cell sorting (FACS) and FlowJo version 7.6.5
software (Tree Star).

Six- to eight-week-old GCSFR−/− and wild-type (WT)
mice were injected in the tail of the pancreas with 1 × 105
murine tumor cells suspended in 50 μl of PBS and Matrigel
(mixed 1:1). Mice were sacrificed at 31 days post-injection
and peripheral blood, bone marrow, and tumors were collected. The bone marrow was extracted from femurs via
high-speed centrifugation, and blood samples were collected in heparinized capillary tubes from retro-orbital
sinus. Blood and bone marrow were washed once with
sterile phosphate buffered saline (PBS) and subjected to
red blood cell (RBC) lysis, according to manufacturer’s
instructions (RBC lysis buffer, Biolegend). We measured
gross wet weight of orthotopic tumors. The tumors were
minced into 2–3-mm-size pieces, mechanically dissociated using the Miltenyi Gentle-MACS tissue dissociator
and digested in enzyme buffer that contained 1 mg/ml collagenase, 2.5 U/ml hyaluronidase and 0.1 mg/ml of DNAse
for 30 min at 37 °C. Digestion mixtures were quenched by
adding DMEM with 10 % FBS and filtered through 70-μm
nylon strainers (BD falcon) and were counted. Pieces of
tumor were also snap frozen in liquid nitrogen. Mice were
injected with 2 × 105 tumor cells in 100 μl PBS subcutaneously, and tumor volume was calculated at specific time
intervals by caliper measurements. We used 7–10 mice per
group, and all these experiments were repeated in triplicate.
All experiments were carried out according to animal studies committee guidelines.

Snap-frozen tissue from mouse and human was homogenized in TRIzol Reagent (Life Technologies), and total
RNA was isolated according to the manufacturer’s guidelines. RNA samples were treated with DNAse (Promega),
and the RNA was extracted with the RNeasy Mini Kit using
the manufacturer’s instructions for RNA clean up (Qiagen).
RNA was reverse transcribed into cDNA using the high
capacity RNA-to-cDNA kit (Life Technologies), and realtime PCR reactions were prepared by mixing cDNA with
Taqman FAST universal PCR Master Mix and pre-designed
Taqman Gene Expression assays (Life Technologies). Realtime PCR was performed on a 7500 FAST Thermal cycler
(Applied Biosystems). Target gene expression was normalized to GAPDH, HPRT, or β-actin. Target gene expression
was determined using the comparative CT (ΔΔCT) method
with 7500 software for 7500 RT-PCR system version 2.0.6
(Applied Biosystems).

Flow cytometry

CD8 suppression assays

Human and mouse single cell suspensions were blocked
with TruStain FcX or anti CD16/32 antibody, respectively
(Biolegend) and stained with fluorescent antibodies using
standard protocols for flow cytometry. To stain ALDHBright
cells, the Aldefluor assay was performed according
to the manufacturer’s protocol (Stem Cell Technologies).

PBMCs were isolated from healthy volunteers by Ficoll
density centrifugation. CD14+ cells were isolated from the
PBMCs of healthy volunteers with the EasySep® Human
CD14 Positive Selection Kit according to the manufacturer’s instructions (Stemcell Technologies™). CD14+
cells were cocultured with BXPC3 or Panc-1 tumor cells

RNA isolation and RT‑PCR
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in a transwell plate to prevent cell to cell contact between
the two populations. The CD14+ cells were mixed 1:1
with autologous PBMCs labeled with 10 μM CFSE (Life
Technologies) in 96-well round-bottom plates (Corning)
coated with 1 μg/ml LEAF™ purified anti-human CD3
(Biolegend, clone OKT3) in complete media [RPMI containing 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml
streptomycin, 1 mM sodium pyruvate (Life Technologies),
and 10 % fetal bovine calf serum (Hyclone)] supplemented
with 100 U/ml of human interleukin 2 (National Institute of
Health). Cell cultures were harvested after 72 h at 37 °C,
and the CFSE dilution of the CD4+ and CD8+ T cell fractions was analyzed by flow cytometry.
In order to test the immunosuppressive properties of
mouse Mo-MDSC, total mouse bone marrow was isolated
from the femur and tibia of WT and G-CSFR−/− mice by
high-speed centrifugation. Bone marrow was subjected to
RBC lysis in Tris lysing buffer (144 mM NH4Cl, 17 mM
Tris–HCl, pH 7.2), and CD11b+ cells were isolated using
the mouse CD11b positive selection kit according to the
manufacturer’s instructions (Stemcell Technologies).
CD11b+ cells were converted into Mo-MDSC by incubating in Pan02-conditioned medium for 72 h at 37 °C in
6-well flat-bottom plates. Tumor-conditioned media was
prepared by incubating Pan02 in complete media in T75
flasks for 72 h at 37 °C followed by 0.2 μm filtration. Single cell suspensions of mouse splenocytes were prepared
by crushing the spleens of WT mice in PBS and filtering
the suspensions over 40 μm filters. Single cell suspensions
were subjected to RBC lysis and splenocytes were labeled
with CFSE as described above. Labeled splenocytes were
cocultured in complete media supplemented with 50 μM
2-mercaptoethanol in 96-well round-bottom plates (Corning) coated with 0.5 μg/ml LEAF™ purified anti-mouse
CD3 (Biolegend, clone 145-2C11) and varying concentrations of CD11b+ cells previously treated with complete
media alone or tumor-conditioned media. In some wells,
arginase-1 activity was inhibited by adding nor-NOHA
(Calbiochem) at a final concentration of 0.5 mM. Cell cultures were harvested after 72 h at 37 °C, and the CFSE
dilution of the CD4+ and CD8+ T cell fractions was analyzed by flow cytometry.
Immunofluorescence
Formalin-fixed paraffin-embedded tissue blocks of archived
human pancreatic ductal adenocarcinoma were cut at 5 μm
using a Leica RM2235 microtome. Cut tissue sections
were then floated onto SuperFrost Plus slides (Fisher Scientific) in a 42 °C water bath and dried overnight. Normal
pancreas tissue previously cut and mounted on glass slides
was purchased from Imgenex. Tissue sections were heated
for 30 min at 65 °C and deparaffinized in three changes of
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xylene. The sections were then rehydrated in serial changes
in decreasing ethanol in deionized water (100, 95, 70,
50 %, then deionized H2O) and rinsed in PBS. Tissue sections were submerged in citrate buffer (10 mM sodium citrate, 0.05 % Tween 20, pH 6) or Target Retrieval Solution
(DAKO, pH 9), and antigen retrieval was performed in a
decloaking chamber (Biocare Medical). The sections were
washed in running deionized water and rinsed in PBS. Tissue sections were then blocked for 30 min at room temperature in Serum-Free Protein Block (DAKO) and stained with
primary antibodies diluted in Antibody Diluent (DAKO)
overnight at 4 °C. The following primary antibodies were
used in this study: mouse anti-ALDH1, clone 44/ALDH
(BD, 1:100); rabbit anti-CD11b, clone M1/70 (Abcam,
1:100); mouse anti-CD14 (Thermo Fisher Scientific Inc.,
1:20); mouse anti-CD15, clone MY-1 (Abcam, 1:10);
mouse anti-keratin 7, clone OV-TL 12/30 (Thermo Fisher
Scientific, 1:50); and mouse anti-phospho-Stat3, clone
D3A7 (Cell Signaling Technology, 1:400). Tissue sections
were washed in PBS then stained with Alexa 488 goat antimouse IgG and Alexa 555 goat anti-rabbit IgG secondary
antibodies (Life Technologies) diluted 1:200 in Antibody
Diluent for 30 min at room temperature. TO-PRO-3 iodide
(Life Technologies) was added to the secondary antibody
cocktail at a final concentration of 1 μM to visualize cellular nuclei. The tissue sections were washed in PBS, and
then, the excess PBS was blotted off and sections were
coverslipped with Vectashield Hard Mounting Media (Vector Labs). Confocal images were acquired on an Axiovert
100M microscope equipped with a LSM 510 META Confocal Laser Scanning Microscope system (Zeiss).
Western blotting
CD14+ cells previously cocultured with Panc-1 tumor
cells (separated by a transwell insert) or cultured in complete media alone. After coculture, CD14+ cells were separated and washed with 1× PBS and lysed in RIPA buffer
containing a protease inhibitor (Roche) and phosphatase
inhibitor (Sigma) cocktails. Cell lysates were sonicated for
10 s then centrifuged at 4 °C for 10 min at 14,000×g. The
supernatant was removed and protein concentration was
determined using a BCA Protein Assay kit (Lamda Biotech,
Inc.,). Twenty microgram of total protein was prepared for
denaturing gel electrophoresis under non-reducing conditions in NuPAGE® LDS buffer according to the manufacturer’s instructions and loaded onto NuPAGE® 4–12 % Bis–
Tris gels in an XCell SureLock Mini-Cell containing 1×
NuPAGE® MOPS SDS running buffer (Life Technologies).
Gels were run at 200 V for 50 min and then blotted onto
PVDF membranes in an XCell Surelock Mini-Cell by wet
transfer with 1× NuPAGE transfer buffer (Life Technologies). After transfer, the blots were rinsed in washing buffer
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(TBST: 20 mM Tris base, 137 mM NaCl, 0.1 % Tween
20, pH 7.6) and blocked in blocking buffer (5 % non-fat
dry milk in TBST) for 1 h at room temperature. The membranes were washed in TBST and incubated in rabbit antiphospho-STAT3 (Cell Signaling Technologies, clone D3A7;
1:2,000) or goat anti-actin (Santa Cruz Biotechnology, Inc.,
1:200) primary antibodies diluted in TBST with 5 % BSA
overnight at 4 °C. Membranes were washed in TBST and
incubated in goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology, Inc., 1:2,000) or donkey anti-goat IgG-HRP
(Santa Cruz Biotechnology, Inc., 1:5,000) diluted in blocking buffer for 1 h at room temperature. The membranes
were washed in TBST and protein bands were visualized
with SuperSignal West Dura Extended Duration Substrate
(Thermo Fisher Scientific). Blot images were acquired with
a ChemiDoc XRS+ imaging system (Bio-Rad).

under refrigeration (2–8 °C) overnight. Bone marrow
cells were isolated from both human and mouse and were
resuspended in PBS with 2 % FBS at 2 × 106 cells/ml.
The cell suspension was added to Methocult medium at
a 1:10 ratio to maintain correct medium viscosity. Three
milliliter of the suspension was drawn and plated in a
35 mm low-adherence petri dish with a loose fitting lid.
The petri dishes were placed in a large petri dish and
incubated in a humidified tissue culture incubator at 37 °C
for 7 days. Granulocyte and macrophage colony-forming units (CFU-GM) were counted at 25× to 50× and a
higher magnification was used to confirm CFU type. The
comparison was made between PC patient bone marrow
and healthy donor bone marrow. For mouse studies, the
comparison was made between GCSFR−/− and WT bone
marrow.

Invasion assays

Coculture experiments with transwell insert

BD BioCoat Matrigel Invasion chambers (Catalog#
354480) were used to study the invasion of tumor cell
lines cocultured with and without CD11b+ or CD14+ cells.
BD BioCoat chambers (24-well) were rehydrated using
bicarbonate-based culture medium. CD11b+ and CD14+
cells were isolated from mice and humans, respectively, as
described above and were plated in the bottom of 6-well
chambers. The transwell inserts were placed in the chamber after 6 h of plating cells. Single cell suspensions of
tumors (BxPC3, Panc-1, KCKO, KCM) were made in culture medium, and 2.5 × 104 tumor cells (in 0.5 ml of culture medium) were added on top of the transwell insert to
assess their ability to migrate/invade (downward) through
the Matrigel-coated membrane. The cells were incubated in
a humidified tissue culture incubator at 37 °C for 22 h. The
non-invading cells were removed from the upper surface of
the membrane using a Q-tip. The cells that invaded through
the Matrigel-coated membrane were then fixed using 100 %
methanol. After fixation, the cells that invaded through
Matrigel membrane were stained using 1 % toluidine blue
(Sigma, Catalog# 198161). The inserts were washed with
diH2O, air-dried, and membranes were removed from the
inserts. The membranes were placed on a microscope slide
with a small drop of immersion oil, and a cover slip was
placed on top. Images of invaded cells were acquired under
microscope at 40× magnification using SPOT RT digital
camera and software. Cells were counted in six different
fields of triplicate membranes.

All cocultures were performed using transwell inserts (BD
Falcon Catalog# 353090) so the tumor cells were separated
from myeloid cells. CD14+ cells or CD11b+ cells suspended in cell culture medium were plated on the 6-well
cell culture plate (costar# 3516). The transwell inserts
were gently transferred into the previously filled wells
(with CD11b+ or CD 14+ cells), and tumor cell suspension was added on top of the transwell insert. Tumor cells
were isolated after coculture by removing the transwell
inserts. CD14+ cells from the bottom were separately harvested. Isolated tumor cells and CD14+ cells were washed,
and flow cytometry RT-PCR, and Western blotting were
performed.

Human and mouse bone marrow colony‑forming unit
(CFU) assay
Methylcellulose-based culture (MC) media (MethoCult, StemCell Technologies Catalog# 03001) was thawed

Statistical analysis
Graphpad prism V (Graphpad Software Inc.,) was used for
statistical analysis. For nonparametric data Mann–Whitney test and for parametric data unpaired t test was used
p < 0.05 was considered statistically significant.

Results
Pancreatic cancer is characterized by abundant
granulocytic and monocytic myeloid cells as well
as ALDH1Bright cancer stem cells
PC tumors possess a dense stroma characterized by abundant immunosuppressive myeloid cells [24]. However,
myeloid cells are heterogeneous with different phenotypes. Therefore, we sought to better characterize these
cells in human PC and found that both CD14+ (monocytic) and CD15+ (granulocytic) myeloid cells were
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highly prevalent by both flow cytometry analysis and
immunofluorescence confocal microscopy (Fig. 1a, b). A
significant population of CD14+ cells within the tumor
had low HLA-DR expression by flow cytometry, a characteristic of Mo-MDSC (Fig. 1a). Unlike PC, however,
normal human pancreas has significantly fewer number
of CD45+ cells (including CD14+, CD15+ myeloid infiltrate) compared with human PC (Fig. 1a, c; Supplementary figures 1, 2).
We hypothesized that the high prevalence of MDSC
in the tumor microenvironment was a result of enhanced
myelopoiesis in the bone marrow of PC patients and active
recruitment to the tumor. In order to study the effect of
tumors on bone marrow myelopoiesis, we measured the
myeloid progenitor cells by performing granulocyte macrophage colony-forming unit assays (CFU-GM) using
bone marrow aspirates of PC patients and healthy controls.
Indeed, bone marrow from PC patients formed significantly
more CFU-GM compared to age-matched healthy controls
(Fig. 1d). This suggests that tumors enhance myelopoiesis
in the bone marrow of PC patients.
As previously stated, ALDH1 defines a subpopulation
of treatment-resistant cancer cells with enhanced tumorinitiating properties in PC [14, 16]. Our group previously reported that ALDH1Bright murine PC cells express
higher levels of CD29, CD44, and CD49f, and we functionally characterized this population of cells by both in
vitro spheroid assays and in vivo tumorigenic potential
in nude mice. We also demonstrated that enrichment of
ALDH1Bright cells promotes chemoresistance in PC [15].
Here, we performed flow cytometry and immunofluorescence staining and found that ALDH1Bright CSCs [identified as CD45−, EpCAM+ and propidium iodide (PI)−]
composed roughly 6–10 % of tumor cells (Fig. 1e)
compared to normal human pancreas (Supplementary
figure 3).
To understand the clinical implications of the CD14+ cell
infiltrate, we analyzed a tissue TMA from 60 PC patients.
Tumors were scored for the presence of CD14+ and leukocytes and stratified into four groups (CD14Hi/CD8Low,
CD14Low/CD8Low, CD14Hi/CD8Hi, and CD14Low/CD8Hi).
We observed that patients with predominant CD14+/
CD8Low infiltrate in the tumor had a significantly reduced
overall survival compared to all other groups (denoted as
CD14Low/CD8Low, CD14Hi/CD8Hi, and CD14Low/CD8Hi,
p value <0.001) (Fig. 1f). Further analysis showed that
CD14+ leukocytes correlated with tumor ALDH1 expression (Spearman’s r = 0.2, p = 0.02) and tumors classified
as CD14Hi had increased ALDH1Bright cells (Supplementary
figure 4). This led us to examine the link between the abundant MDSC infiltrate and the ALDH1Bright CSC sub population, which is a well-established cancer stem cell population in murine PC model [15].
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GCSFR−/− mice with pancreatic cancer exhibit impaired
myelopoiesis
To further study the potential relationship between tumorinduced bone marrow myelopoiesis and increased ALDH1Bright CSCs in tumors, we employed a mouse model.
Granulocyte colony-stimulating factor (G-CSF/CSF-3) is
a critical growth factor for myeloid cell production in the
bone marrow [25, 26]. We utilized a G-CSF receptor knock
out (GCSFR−/−) mouse model (on a C57BL/6 genetic background) to study the effects of myelopoiesis in PC. These
mice are unique in that they cannot increase myelopoiesis
in response to physiologic triggers, including tumors [25,
27]. We utilized three distinct murine PC cell lines, denoted
as KCM, KCKO, and Pan02, derived from spontaneous
PC arising from genetic models (LSL-KRASG12D × P48Cre × MUC1 and LSL-KRASG12D × p48-Cre, respectively) or tumors arising from 3-methylcholanthrene
carcinogenesis (Pan02) [23]. We implanted tumor cells
subcutaneously in WT and GCSFR−/− mice and isolated
bone marrow from both tumor bearing and non tumor bearing mice. Tumor bearing GCSFR−/− mice had significantly
less CFU-GM as compared to WT mice ex vivo (Fig. 2a).
Similar to PC patients, we observed an increase in bone
marrow myelopoiesis and MDSC (CD11b+, Gr1+) in the
peripheral blood of tumor-bearing WT mice [7]. In vivo,
GCSFR−/− mice were not able to upregulate myelopoiesis
in response to PC implantation, which translated into significantly reduced G-MDSC and Mo-MDSC in the blood
of tumor-bearing mice (Fig. 2b). However, MDSC from
tumor-bearing WT and GCSFR−/− mice were similarly
immunosuppressive ex vivo (Supplementary figure 5). We
have studied the direct ligand-receptor expression and identified that tumor cells do not express GCSF receptor (data
not shown). This suggests that while GCSFR−/− mice have
reduced myelopoiesis, their myeloid cells retain immunosuppressive properties, thus meeting the definition of
MDSC [28].
MDSC reduction alters the tumor microenvironment
and correlates with decreased frequency of ALDH1Bright
CSCs in murine pancreatic cancer
Because PC is characterized by an abundant stroma where
myeloid cells predominate, we sought to determine the relationship between MDSC and ALDH1Bright CSCs using the
GCSFR−/− mouse model. GCSFR−/− mice have significantly
decreased tumor-infiltrating G-MDSC and Mo-MDSC, compared to WT tumors. In addition, there was a corresponding
increase in tumor-infiltrating CD8+ T cell infiltrate while
CD4+ T cells and macrophages (defined as CD45+/CD11b+/
F4/80hi/Ly6Clow/MHCII+) were unchanged (Fig. 2c). The
bar graph shows infiltrating tumor cells as a percentage of

Cancer Immunol Immunother (2014) 63:513–528

Fig. 1  Myeloid cells and ALDH1Bright cells are prevalent in PC. a Flow
cytometry performed on human PC samples (N = 11) and normal human
pancreas (N = 4). Representative flow cytometry plot of normal human
pancreas and PC tumor compares CD45+ infiltrate. Flow cytometry
plots gating on CD45+ cells shows CD14+ and CD15+ infiltrate in the
tumor. A significant population of CD14+ cells is HLA-DRlow/−. A representative flow plot shows 2.68 % CD45+ cells infiltrating the normal
human pancreas (gating is performed using isotype control). b Immunofluorescent staining was performed on normal human pancreas samples
(N = 5) and PC samples (N = 5). Representative immunofluorescent
confocal images (×63) of normal human pancreas and PC stained for
(CD11b, CD14), (CD11b, CD15). Green CD14 or CD15, red CD11b
and blue Topro. c A histogram reporting percentages (average values)
of the monocytic and granulocytic myeloid cells and T cells infiltrating
the tumor as a percentage of total cells in PC tissue (N = 11) compared
to normal human pancreas (N = 4). Granulocytes (normal pancreas
(mean ± SD) = 1.87 ± 0.5 and PC = 14.6 ± 0.65, p value <0.05) and
monocytes (normal = 1.3 ± 0.7 and PC = 12.4 ± 1.07, p value <0.05)
are significantly increased in PC. d Upregulation of myelopoiesis in
human PC; bone marrow specimens were collected from PC patients
(N = 16) and age-matched healthy controls (N = 7); methylcellulose-
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based colony-forming unit assays were performed as described in “Materials and methods” section and were scored for the total number of myeloid colonies (CFU-GM) after 8 days. Bar graph depicts mean ± SEM
and asterisk denotes statistically significant difference between the two
groups p < 0.05 by Mann–Whitney test. e ALDH1 activity in human PC
(N = 11); representative flow cytometry plot of human PC tumor gated
on live EpCAM+ cells using Aldefluor assay. Immunofluorescent staining was performed on PC samples (N = 5) and normal human pancreas
samples (N = 5). Representative immunofluorescence confocal images
(×63) of normal human pancreas and PC stained for EpCAM, ALDH1
(green ALDH1, red EpCAM and blue Topro). Arrows point toward ducts
expressing ALDH1 activity. f The CD14–CD8 ratio predicts PC patient
survival. Automated analysis of CD14+ and CD8+ IHC reveals the relationship between leukocyte density and overall survival. The Kaplan–
Meier estimate of overall survival comparing CD14Hi/CD8Low, CD14Low/
CD8Low, CD14Hi/CD8Hi, and CD68Low/CD8High, is shown. Patients
with predominant CD14+/CD8Low infiltrate in the tumor had a significantly reduced overall survival compared to all other groups (denoted as
CD14Low/CD8Low, CD14Hi/CD8Hi, and CD14Low/CD8Hi). There is a statistically significant difference between CD14Hi/CD8Low and CD14Low/
CD8Hi, p value <0.001
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Fig. 2  Myeloid cells promote CSCs and EMT in murine PC. a
CFU-GM in bone marrow; bone marrow was isolated from tumorbearing and non-tumor-bearing WT and GCSFR−/− mice (N = 7–10
mice/group), methylcellulose-based colony-forming unit assays
were performed and scored for total number of myeloid (CFUGM) colonies after 8 days. Tumor-bearing WT mice have significantly increased myeloid colonies (CFU-GM) as compared
to non-tumor-bearing WT mice. GCSFR−/− mice have significantly decreased CFU-GM as compared to non-tumor-bearing WT
mice (NTB non-tumor-bearing, TB tumor-bearing). b Peripheral
blood G-MDSC (CD11b+/Gr1+/Ly6G+/Ly6Cmid) and Mo-MDSC
(CD11b+/Gr1+/Ly6G−/Ly6Chi) calculated as a percentage of total
cells. Data are shown for NTB and TB WT and GCSFR−/− mice. c
Analysis compares tumor myeloid and lymphoid infiltrate by flow
cytometry in WT and GCSFR−/−, KCM tumor-bearing mice. MoMDSC = CD11b+/Gr1+/Ly6G−/Ly6Chi/F4/80mid, G-MDSC = CD11
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b+/Gr1+/Ly6G+/Ly6Cmid, T cells = CD45+/CD3+/CD4+, or CD8+,
TAM = CD45+/CD11b+/F4/80hi/Ly6Clow/MHCII+. d Bar graph
shows fold gene expression change in GCSFR−/− tumors relative to
WT tumors. e Representative flow cytometry plot showing mouse
orthotopic PC specimens stained for ALDH1 activity. Analysis by
flow cytometry demonstrated approximately 8.2 % ALDH1Bright
CSCs in WT tumors and 3.58 % in GCSFR−/− tumors. Bar graph
shows fold gene expression of Slug, Nanog, Twist, Snail, ZEB-1, and
OCT-4 in GCSFR−/− tumors relative to WT tumors. f Tumor growth
curves comparing subcutaneous tumor growth, KCM by caliper
measurements in WT mice and GCSFR−/− mice. Points on curve represent mean values ± SEM at indicated time points. Bar graph compares tumor weights of orthotopically implanted KCM in WT and
GCSFR−/− mice 31 days post-injection. It depicts mean ± SEM and
asterisk denotes statistically significant difference between the two
groups p < 0.05 by Mann–Whitney test
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total cells. We also compared the tumor infiltrate in WT
tumors that had different volumes (0.4 and 1.0 cm3) to rule
out the possibility that the differences in the G-MDSC and
Mo-MDSC infiltrate are due to different tumor sizes (Supplementary figure 6 D). Furthermore, GCSFR−/− mice
exhibit a shift in the immune profile of PC tumors from a
TH-2 to TH-1 immune response, characterized by increased
expression of IFN-γ, TNF-α and IL-12 with decreased
expression of arginase-1, IL-6, TGF-β, IL-10 compared to
WT mice (Fig. 2d). Interestingly, tumors from GCSFR−/−
mice had significantly reduced ALDH1Bright CSCs compared
to those from WT mice (Fig. 2e). GCSFR−/− tumors also
displayed decreased expression of genes associated with cell
pluripotency (i.e. Oct-4 and Nanog) and EMT (i.e. Snail,
Slug, Twist and Zeb-1 by RT-PCR) (Fig. 2e). This suggests
that the absence of MDSC in GCSFR−/− tumors is associated with a decrease in ALDH1Bright CSCs.
Ultimately, this was associated with significantly
decreased tumor growth in both subcutaneous and orthotopic PC tumors in GCSFR−/− mice (Fig. 2f). These findings suggest an enhanced antitumor immune response
in GCSFR−/− mice is associated with reduced bone marrow-derived MDSC in the tumor. Similar results were
found using other murine PC cell lines (Supplementary
figure 6A–C).
Monocytic MDSC directly increase the frequency
of ALDH1Bright CSCs in murine PC
Since decreased tumor-infiltrating MDSC were associated
with reduced ALDH1Bright CSCs, we hypothesized that
MDSC contribute to expanding the population of ALDH1Bright CSCs. To test this, we utilized an in vitro model
utilizing murine cell lines in order to exclude the possibility of involvement of other cell types. We cocultured in
vitro-maintained KCM with myeloid cells from the bone
marrow of tumor-bearing mice (cells were separated by
transwell insert). The frequency of ALDH1Bright CSCs and
CD24+, CD44+ CSCs was significantly increased in KCM
cocultured with CD11b+ cells, compared to KCM alone
(Fig. 3a). However, MDSC are composed of both MoMDSC and G-MDSC and perhaps only one of these two
subsets were responsible for this observation. Therefore,
we isolated Mo-MDSC and G-MDSC from the tumors of
WT mice by FACS and cocultured these cells separately
with KCM. We found that the frequency of ALDH1Bright
CSCs was significantly increased when KCM was cocultured with Mo-MDSC while there was no increase with
G-MDSC, separated by transwell insert (Fig. 3b). This
suggests that Mo-MDSC enhance the ALDH1Bright and
CD24+, CD44+ CSCs in PC. In order to validate this finding, we also cultured murine PC tumor cells for sphere
formation after they were cocultured with myeloids. The
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spheres were harvested and then implanted subcutaneously
in WT mice, and tumor growth was compared to non cocultured tumor cells. The tumors grew faster when the tumor
spheres were implanted after coculture with myeloid cells
compared to the spheres that were not cocultured with
myeloid cells (Fig. 3c). We also assessed changes in the
expression of markers promoting epithelial to mesenchymal transition and performed functional studies. The tumor
cells were separated from Mo-MDSC after coculture, and
RT-PCR and Western blotting were performed. There was
downregulation of E-cadherin and upregulation of vimentin in the tumor cells that were previously cocultured (separated by a transwell insert) with myeloid cells (Fig. 3d).
Invasion studies further supported that tumor cells that
were previously cocultured with myeloid cells had a mesenchymal phenotype and significantly invaded the Matrigel
plug compared to the tumor cells that were not cocultured
with myeloid cells (Fig. 3e). This suggests that Mo-MDSC
promote CSCs in murine PC and promote mesenchymal
properties of tumor cells.
Human pancreatic cancer converts circulating monocytes
into Mo‑MDSC
In order to study the role of Mo-MDSC in human PC, we
cocultured normal human blood monocytes with human
PC cell lines (Panc-1 and BxPC3). The CD14+ cells were
harvested and assessed by flow cytometry, immune suppression, RT-PCR, and Western blotting. These monocytes acquired a Mo-MDSC phenotype characterized
by a significantly decreased expression of HLA-DR and
increased expression of arginase-1 as well as the ability
to suppress CD8+ T cell proliferation in vitro [29–32]
(Fig. 4a–c). See supplementary figure 7 for similar results
using the BxPC3 cell line. Thus, tumor-derived factors in
PC are capable of changing the phenotype and functionality of human blood monocytes, converting these cells
into immunosuppressive Mo-MDSC. In PC patients with
primary disease only, the CD14+ cells in the blood have
a high HLA-DR expression but these cells only obtain
MDSC phenotypic markers when they infiltrate the tumor
(Fig. 4d).
Mo‑MDSC promote stemness in human PC by a
STAT3‑dependent mechanism
Since Mo-MDSC in mice increase the prevalence of ALDH1Bright CSCs and enhance expression of genes associated
with EMT in murine PC, we sought to determine if the
same phenomenon occurs in human PC. We generated MoMDSC in vitro as described above and cocultured these
cells with PC cell lines in vitro. Both Mo-MDSC and tumor
cells were analyzed by flow cytometry and RT-PCR after
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Fig. 3  a KCM cultured alone and with CD11b+ cells isolated from bone
marrow of WT tumor-bearing mice by magnetic bead isolation, for 72 h.
KCM tumor cells were isolated and stained for ALDH1 activity and other
CSC markers. Representative flow cytometry plots show ALDH1Bright
CSCs, which constitute approximately 4.17 % when KCM is cultured
alone and increase up to 8.09 % after coculture with CD11b+ cells. Bar
graph shows percentage ALDH1Bright and CD24+, CD44+ cancer stem
cells in KCM, with and without coculture with CD11b+ cells. b G- and
Mo-MDSC were isolated from orthotopically implanted KCM tumors of
WT mice by FACS. These cells were separately cocultured with KCM
for 72 h. After 72 h, KCM cells were isolated and stained for ALDH1
activity. Representative flow cytometry plots show that ALDH1Bright
CSCs constitute approximately 4.39 % when KCM is cultured alone,
5.08 % when KCM cocultured with G-MDSC and increases up to 8.5 %
when KCM is cocultured with Mo-MDSC. c Tumor growth curves comparing subcutaneous tumor growth, KCM spheres (with baseline ALDH1
activity) and KCM spheres after coculture (increased ALDH1 activity) by

13

Cancer Immunol Immunother (2014) 63:513–528

caliper measurements in WT mice. Points on curve represent mean values ± SEM at indicated time points. d CD11b+ cells were isolated after
coculture with tumor cells in transwell plates and were used for Western
blotting. Western blot analysis of KCM shows downregulation of E-cadherin and upregulation of vimentin in KCM from baseline after coculture
with CD11b+ cells. e Invasion assays were performed to compare the
invading properties of tumor cells. Tumor cells were seeded in the upper
part of Matrigel-coated transwell inserts. Cell invasion index was calculated as the number of cells attached to the bottom of Matrigel-coated
membrane. Figure shows that KCM tumor cells have increased invasion
through Matrigel matrix membrane after coculture relative to tumor cells
alone. Cells per high-power field were quantified. Cells were counted in
six different fields of triplicate membranes. Graph depicts the number of
invaded cells per high-powered field (mean ± SEM of three independent experiments). Asterisks denotes statistically significant difference
between the two groups p < 0.05 by Mann–Whitney test. We used 7–10
mice per group and all these experiments were repeated in triplicate
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Fig. 4  CD14+ cells were isolated from normal human PBMC by
magnetic bead isolation and were cocultured with human PC cell
line Panc-1 for 72 h. a Downregulation of HLA-DR expression after
tumor exposure; flow cytometry was performed on CD14+ cells
(from blood) after 72 h of coculture with tumor cells. Representative
plots show that approximately 83.5 % CD14+ cells had high HLADR expression when these cells are incubated in complete medium
(CM). After tumor exposure, these cells downregulate HLA-DR
expression and 71.4 % CD14+ cells have low HLA-DR expression. b
Analysis of quantitative RT-PCR results for gene expression of argin-

ase-1 from CD14+ cells cocultured with and without tumor. Normalized fold change is depicted. c Representative flow cytometry histogram from T cell suppression assay depicts stimulated, CFSE-labeled
CD8+ T cells cocultured with tumor-conditioned or unconditioned
CD14+ cells for 72 h. d Representative flow cytometry plot shows
differential expression of HLA-DR on CD14+ cells isolated from the
blood and human tumor specimens. Bar graphs depict mean division
index ± SEM with asterisk denotes p < 0.05 by Mann–Whitney in all
panels

coculture. Consistent with our findings in mice, Mo-MDSC
increased the ALDH1Bright and CD24+, CD44+ CSC population in BxPC3 after coculture as compared to control
tumor cells (Fig. 5a). In order to validate this finding, we
also cultured human PC tumor cells for sphere formation
after they were cocultured with CD14+ cells. The spheres
were isolated and implanted subcutaneously in NU/J mice
and tumor growth was compared to non-cocultured tumor
cells. The tumors grew faster when the tumor spheres were
implanted after coculture with Mo-MDSC, compared to
spheres that were not cocultured with Mo-MDSC (Supplementary figure 8). Consistent with enhanced tumor-initiating properties, we observed that the transcription factors

associated with cell pluripotency and EMT, i.e., Snail,
Slug, Twist, Zeb-1, Nanog, and Oct-4 were significantly
increased by RT-PCR in PC cells cocultured with MoMDSC. Invasion studies showed that the tumor cells that
were previously cocultured with Mo-MDSC have significantly increased invasion activity (Fig. 5b). Similar results
were seen using Panc-1 (Supplementary figure 9). This
suggests that human Mo-MDSC promote tumor stemness
and EMT. Additionally, we found that IL-6 expression
was upregulated in the Mo-MDSC as compared to normal
monocytes (Fig. 5c).
STAT3 activity in tumor cells has been demonstrated to
facilitate the expansion and maintenance of CSCs in several
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tumor types [17]. However, we hypothesized that up regulation of signal transducer and activator of transcription 3
(pSTAT3) in Mo-MDSC is involved in promoting ALDH1Bright CSCs in PC. CD14+ cells were isolated from tumor
cells after coculture and Western blotting was performed.
We observed that there was upregulation of phosphorylated STAT3 in tumor-treated CD14+/HLA-DRlow/− cells
as compared to untreated CD14+ cells by Western blotting (Fig. 5d). We also found upregulation of pSTAT3 in
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CD11b+ cells after coculture with murine PC cell lines
(Supplementary figure 10). In order to determine if pSTAT3
mediated the ability of Mo-MDSC to increase the prevalence of ALDH1Bright CSCs, Mo-MDSC were treated with
STATTIC, a small molecule inhibitor of STAT3 [21] and
washed with PBS. STATTIC-treated cells were then plated
in a 6-well plate, and a transwell insert was placed on
top of the cells. Human PC tumor cells were added to the
transwell insert and were cultured for 72 h. We found that
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◂ Fig. 5  STAT3 activity in Mo-MDSC promotes CSCs and EMT in

PC. a CD14+/HLA-DRlow/− cells were cocultured with BxPC3 for
72 h and ALDH1, CD24, and CD44 staining was performed. Graph
shows ALDH1Bright CSCs and CD24+, CD44+ cells as a percentage
of CD45−, EpCAM+, PI− cells. b Tumor EMT markers and invasion assay; RT-PCR shows that markers of cell pluripotency and
EMT were upregulated in BxPC3 tumor cells after coculture with
CD14+/HLA-DRlow/− cells. Invasion assays showing that BxPC3
tumor cells have increased invasion through Matrigel matrix membrane after coculture with CD14+ cells relative to tumor cells alone.
Cells per high-power field were quantified. Graph depicts the number of invaded cells per high-powered field (mean ± SEM of three
independent experiments). c Analysis of quantitative RT-PCR results
for expression of IL-6 by CD14+ cells cocultured with and without
BxPC3 tumor. Normalized fold change is depicted. d Western blot
analysis of STAT3 phosphorylation in CD14+ cells cocultured with
and without BxPC3 tumor cells for 72 h. e Inhibition of STAT3
signaling in CD14+/HLA-DRlow/− cells prevents the increase in
ALDH1Bright CSCs in BxPC3 from baseline. CD14+ cells treated
with STATTIC were washed and then cocultured with tumor cells
in transwell plates. Bar graph shows ALDH1Bright CSC population (gated on CD45−, EpCAM+, PI− cells) which is approximately
8.79 % in BxPC3 alone, 15.8 % when BxPC3 was cocultured with
CD14+/HLA-DRlow/− cells and 6.02 % when BxPC3 was cocultured
with STATTIC-treated CD14+/HLA-DRlow/− cells. Graph shows
that inhibition of STAT3 signaling by STATTIC (20 μM) blocks the
increase in frequency of ALDH1Bright cells from baseline. f Bar graph
shows tumor spheroid formation in BxPC3 and Panc-1 cells with and
without CD14+/HLA-DRlow/− cells in the coculture. The mean number of tumor spheroids formatted after 10 days is depicted. g Representative immunofluorescence confocal images (×63) of human PC
stained for CD14+ cells and pSTAT3 activity. Green CD14 and red
pSTAT3. Bar graphs depict mean division index ± SEM with asterisk denotes p < 0.05 by Mann–Whitney in all panels

treatment with STATTIC entirely prevented the Mo-MDSC
mediated increase in ALDH1Bright CSCs (Fig. 5e). In addition, we performed tumor sphere-forming assays, which
display an increased tumor spheroid formation compared to
control tumor cells in vitro, and treatment with STATTIC
significantly decreased the Mo-MDSC mediated increase in
sphere formation (Fig. 5f).
STAT3 signaling in MDSC can be modulated by IL-6
[33, 34], which has been shown to enhance CSCs and EMT
in cancer. While we found that IL-6 mRNA gene expression was significantly downregulated by STAT3 inhibition
(Supplementary figure 11), IL-6 blockade using anti-IL-6
antibodies decreased but did not fully reverse the effect of
Mo-MDSC on increasing the prevalence of ALDH1Bright
CSCs. This suggests that the effects of Mo-MDSC on promoting tumor stemness are likely mediated by multiple
factors downstream of pSTAT3. Finally, to confirm that
CD14+ cells express pSTAT3 in vivo, we performed immunofluorescence staining for CD14 and pSTAT3 in human
PC. Indeed, the majority of CD14+ leukocytes in the tumor
microenvironment expressed pSTAT3 (Fig. 5g). These data
suggest that pSTAT3 positive Mo-MDSC play an important role in PC progression by enhancing the population of
ALDH1Bright CSCs and promoting EMT.

Fig. 6  Activation of pSTAT3 in the Mo-MDSC enhances the CSCs
in the PC tumor

Discussion
PC is unique for its dense infiltrate of myeloid cells with
a paucity of T cells. Myeloid recruitment is critical to the
establishment and progression of PC. Tumors communicate with the bone marrow to increase myelopoiesis in
both tumor-bearing mice and human PC patients. These
myeloid cells are then recruited to the tumor microenvironment where they enhance growth and metastasis. In
this study, we demonstrate the importance of MDSC on
promoting the ALDH1Bright CSCs in PC tumors. In our
GCSFR−/− mouse model, we found that the reduction
in MDSC in the tumor decreases the ALDH1Bright CSC
population. We also found that the expression of EMT
markers and stem cell genes were downregulated in the
tumors of GCSFR−/− mice. We further demonstrate that
Mo-MDSC in human PC promote cancer stemness in a
STAT3-dependent manner.
In our experiments, we found that monocytes can
become Mo-MDSC, as they downregulate HLA-DR
expression and suppress T cell proliferation in the presence
of tumor cells or tumor-derived factors (Fig. 6). This is
important as it suggests that even mature human monocytes
can acquire immunosuppressive properties upon exposure
to tumor-derived factors. We have previously demonstrated
that increased peripheral blood monocyte counts correlate with decreased survival in PC patients [35]. The data
presented here suggest that the phenotype and functional
traits of human monocytes depend on the immune environment to which these cells are exposed. Therefore, targeting monocytes in the circulation is an attractive and novel
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approach, which could decrease Mo-MDSC in the tumor
microenvironment.
ALDH1 enzyme activity defines a subpopulation of
tumor cells which exhibit stem cell-like properties and
whose prevalence correlates with survival in PC Additionally, a number of cell surface markers are co-expressed
with ALDH1, such as CD44, CD24, CD133, and CXCR4
[36, 37]. Evidence in mice suggests that ALDH1 has an
important role in the embryological development of the
pancreas [38, 39]. However, a subpopulation of ALDH1Bright CSCs exhibit enhanced chemoresistance and metastasis [15]. Despite much progress, further work is needed to
find better phenotypic and functional markers of CSCs in
human malignancy.
STAT3 is a crucial transcription factor involved in
inflammation. In murine models, pSTAT3 has been shown
to regulate the expansion of myeloid progenitors as well as
MDSC [40, 41].
Mo-MDSC depend on STAT3 for their immunosuppressive properties, such as the production of arginase-1 [30].
We show here that STAT3 activation in Mo-MDSC is also
critical for enhancing the CSC population in PC. It is likely
that STAT3 phosphorylation reprograms monocytes to
acquire a pro-tumor, immunosuppressive (MDSC) phenotype. We show that STAT3 inhibition completely abrogates
the ability of Mo-MDSC to enhance the ALDH1Bright CSC
population in vitro.
Bone marrow-derived myeloid cells make up a significant proportion of the stroma in solid tumors where
they promote proliferation and survival of tumor cells.
Recent reports demonstrate that tumor-infiltrating macrophages support early tumorigenesis by inducing EMT
through TGF-β signaling [42]. In addition, other studies have shown that there is cross talk between MDSC
and macrophages that polarizes macrophages into an
M2 phenotype [43] which contribute to EMT [44]. Like
macrophages, the high frequency of Mo-MDSC-infiltrating tumors suggests these cells are critical in mediating immune suppression in cancer patients. Our murine
model and in vitro studies confirm that in addition to the
direct suppression of T cells, Mo-MDSC also play an
important role in promoting tumor stemness and EMT
in a STAT3-dependent manner and this effect is independent of any other cell type in the tumor. Our data
further show that Mo-MDSC and macrophages can be
distinguished based on expression of HLA-DR (Figs. 4,
5). Thus, we conclude that both Mo-MDSC and macrophages promote EMT, but further studies are required
to assess possible mechanistic, spatial, and/or temporal
differences.
Overall, our study shows that Mo-MDSC in both mice
and humans promote ALDH1Bright CSCs in PC through
STAT3 activation. Therefore, an improved understanding
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of the interactions between MDSC and CSCs is crucial for
the development of novel therapies that may intercept this
communication. Our findings suggest that there are multiple pathophysiologic pathways, which could be therapeutically targeted in PC. Blocking tumor-induced myelopoiesis [45], the recruitment of monocytes to the tumor
microenvironment, e.g., through blockade of chemokine
receptors, the conversion of monocytes into Mo-MDSC,
and the STAT3-dependent enhancement of tumor stemness
all offer opportunities to thwart the tumor-promoting
effects on myeloid cells in this disease. In conclusion, we
show that monocytes can become Mo-MDSC in the presence of tumor by acquiring immunosuppressive properties.
Furthermore, Mo-MDSC infiltrate tumors where they promote cancer stemness in a STAT3-dependent manner.
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